Groundbreaking EV isolation technology enabling minimally invasive human disease screening, diagnosis, and treatment monitoring.
For decades, understanding disease at the molecular level has meant invasive tissue biopsies — painful to obtain, hard to repeat, and often impossible to access safely. Captis is rewriting that standard. Every cell continuously releases extracellular vesicles into blood and other bodily fluids, carrying the same tumor-derived DNA, RNA, and protein cargo found in solid tissue. By capturing and analyzing these vesicles, we turn a simple blood draw into a window on disease — enabling diagnostics that are minimally invasive, repeatable, and fast enough to keep pace with how a patient is actually doing.
Our primary mission at Captis Diagnostics is to spearhead the advancement and commercialization of cutting-edge research tools for human disease research and clinical diagnostics, anchored by our Lipid Nanoprobe (LNP) platform, which enables rapid, high-efficiency extracellular vesicle isolation from human biofluids.
Captis Diagnostics envisions a future where our EVs-based liquid biopsy technology empowers researchers and healthcare providers to create minimally invasive diagnostic tools and assays for human diseases. These innovative diagnostic assays will provide medical doctors with actionable insights for treating human diseases, ultimately leading to improved patient outcomes.
LNP leverages the fundamental structural characteristic of EVs — their outer bilayer lipid membrane — to isolate them with unmatched efficiency and specificity.
The LNP system uses two nanomaterial components: a lipid-based labeling probe (lipid-PEGm-biotin) that inserts into the lipid membrane through self-assembly to instantly tag EVs, and magnetic nanospheres (MNS) surface-modified with NeutrAvidin to collect the tagged EVs magnetically.
Read the original LNP paper →
Starting from a raw bodily fluid sample, LNP isolates EVs through a single magnetic separation — no ultracentrifugation or specialized equipment required.
After a short incubation, LNP-bound EVs are magnetically precipitated, washed, and prepared for downstream protein, DNA, and RNA analysis — the full workflow takes 15 minutes or less.
LNP-isolated EVs harbor high-quality nucleic acids (DNA and RNA) and unique proteins, supporting DNA mutation detection, RNA sequencing, and proteomics from a single blood draw.
Reference: Y. Wan, et al. Rapid magnetic isolation of extracellular vesicles via lipid-based nanoprobes. Nature Biomedical Engineering 1 (2017) 0058.
LNP-isolated extracellular vesicles carry actionable tumor-derived DNA directly from patient plasma, enabling non-invasive genomic profiling even when tissue biopsy is difficult to obtain or repeat. In a cohort of non-small cell lung cancer (NSCLC) patients, LNP technology was used to isolate EVs from a single blood draw and interrogate them for clinically relevant alterations.
DNA point mutations (KRAS, EGFR) and gene fusions (ALK-ELM4) were successfully detected in LNP-isolated EVs from plasma of non-small cell lung cancer patients, demonstrating clinical-grade sensitivity for actionable genomic alterations. Across the 13 patients tested, EV-based results matched tissue biopsy findings in all but one case, supporting plasma EVs as a reliable, minimally invasive alternative for genomic alteration detection.
| Patient | Mutation | Tissue | Plasma EV |
|---|---|---|---|
| KRAS Mutation | |||
| 1 | G12C | MU | MU |
| 2 | G12C | MU | MU |
| 3 | G12S | MU | MU |
| 4 | G12S | MU | MU |
| 5 | G13C | MU | MU |
| 6 | G12A | MU | WT |
| 7 | Q61H | MU | MU |
| EGFR Mutation | |||
| 8 | EGFR L858R | MU | MU |
| 9 | EGFR L858R | MU | MU |
| 10 | EGFR Exon19 del | MU | MU |
| EML4-ALK fusion | |||
| 11 | Variant 3a/b | Positive | Positive |
| 12 | Variant 3a/b | Positive | Positive |
| 13 | Variant 3a/b | Positive | Positive |
In a prospective study of 44 patients with KRAS-mutated pancreatic ductal adenocarcinoma (PDAC) undergoing neoadjuvant therapy and surgery, LNP-isolated plasma EVs were used to track KRAS mutation allele frequency (MAF) over the course of treatment. Patients with rising EV-KRAS MAF had significantly shorter disease-free and overall survival than those with stable or decreasing MAF, and this trend independently predicted survival outcomes on multivariable analysis.
Read the full paper →
Two purpose-built isolation kits — one optimized for multi-omics discovery, one for in-depth proteomics and mass spectrometry. Both powered by Captis's proprietary magnetic bead technology.
Practical guidance for EV isolation and downstream DNA, RNA, and protein workflows.
Practical guidance for EV enrichment and downstream protein biomarker and LC-MS/MS workflows.
Dr. He is a medical diagnostics entrepreneur with significant expertise in EV isolation and molecular diagnostic assay development. He has received extensive training in business development through TechCelerator, NIH I-Corps, LifeX Lab, and NSF I-Corps. He has focused on developing EV-based minimally invasive technology for human disease diagnosis, along with ddPCR and next-generation sequencing molecular diagnostic assays. Dr. He has authored over 50 publications with 3,675 citations on Google Scholar, and holds 1 issued patent with 5 patent applications.
Dr. Milosevic is an accomplished researcher and R&D scientist with extensive experience in epigenetics, biomarker discovery, and EV research. Her primary objective is to develop minimally invasive liquid biopsy tools as routine diagnostic tests for human disease. Over more than 15 years, she has acquired substantial expertise and has authored 25 scientific publications. She has played various roles from mentoring junior scientists to leading independent and collaborative research.
Dr. Park is a molecular biologist and bioinformatician with expertise in next-generation sequencing, epigenomics, and extracellular vesicle research. He completed his Ph.D. in Genetics at the University of Rochester School of Medicine and Dentistry, where his doctoral work focused on developing novel genomic technologies including Cas-CUT&Tag and CUT&Tag-based epigenomic profiling. At Captis Diagnostics, he leads development of LEVR-Seq (long-read Nanopore sequencing for EV-derived RNA isoform and gene fusion detection) and EV-EPIC (CUT&Tag epigenomic profiling from EV-derived chromatin), and serves as Principal Investigator on NIH SBIR-funded projects.
Captis Diagnostics is a growing team working at the intersection of nanotechnology, oncology, and molecular diagnostics. If you're passionate about making minimally invasive disease detection a clinical reality, we'd love to hear from you.
Further information available upon request. Please provide some details on your project or goals and we'll move the conversation forward from there.